DRUG TARGETING BY RETROMETABOLIC DESIGN: SOFT DRUGS AND CHEMICAL DELIVERY SYSTEMS

REFERENCES

• Widder K. J., Senyei A. E., Rannes D. F. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. Adv. Pharmacol. Chemother. 1979; 16: 213
   PubMedGoogle Scholar
• Poste G., Kirsh R., Koestler T. The challenge of liposome targeting in vivo. Liposome Technology, G. Gregoriadis. CRC Press, Boca Raton 1984; 3: 1
   Google Scholar
• Poznansky M. S., Juliano M. S. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol. Rev. 1984; 36: 277
   PubMed Web of Science ®Google Scholar
• Gardner C. R. Potential and limitations of drug targeting: an overview. Biomaterials 1985; 6: 153
   PubMed Web of Science ®Google Scholar
• Tomlinson E. E., Davis S. S.E. Site-Specific Drug Delivery: Cell Biology, Medical, and Pharmaceutical Aspects. John Wiley and Sons, New York 1987
   Google Scholar
• Ranade V. V. Drug delivery systems. 1. Site-specific drug delivery using liposomes as carriers. J. Clin. Pharmacol. 1989; 29: 685
   PubMed Web of Science ®Google Scholar
• Meijer D. K.F., Jansen R. W., Molema G. Drug targeting systems for antiviral agents: options and limitations. Antiviral Res. 1992; 18: 215
   PubMed Web of Science ®Google Scholar
• Themed issue. Targeting of drugs and delivery systems, S. M. Moghimi, 1995; 17: 1, Adv. Drug Deliv. Rev.
   Google Scholar
• Friend D. R., Pangburn S. Site-specific drug delivery. Med. Res. Rev. 1987; 7: 53
   PubMed Web of Science ®Google Scholar
• Tomlinson E. Theory and practice of site-specific drug delivery. Adv. Drug. Del. Rev. 1987; 1: 87
   Google Scholar
• Bodor N., Gabanyi Z., Wong C.-K. A new method for the estimation of partition coefficient. J. Am. Chem. Soc. 1989; 111: 3783
   Web of Science ®Google Scholar
• Bodor N., Harget A., Huang M.-J. Neural network studies. 1. Estimation of the aqueous solubility of organic compounds. J. Am. Chem. Soc. 1991; 113: 9480
   Web of Science ®Google Scholar
• Bodor N., Huang M.-J. An extended version of a novel method for the estimation of partition coefficients. J. Pharm. Sci. 1992; 81: 272
   PubMed Web of Science ®Google Scholar
• Bodor N., Huang M.-J. A new method for the estimation of the aqueous solubility of organic compounds. J. Pharm. Sci. 1992; 81: 954
   PubMed Web of Science ®Google Scholar
• Bodor N., Buchwald P. Molecular size based approach to estimate partition properties for organic solutes. J. Phys. Chem. B 1997; 101: 3404
   Web of Science ®Google Scholar
• Buchwald P., Bodor N. Octanol-water partition of nonzwitterionic peptides: predictive power of a molecular size based model. Proteins 1998; 30: 86
   PubMed Web of Science ®Google Scholar
• Buchwald P., Bodor N. Molecular size-based model to describe simple organic liquids. J. Phys. Chem. B 1998; 102: 5715
   Google Scholar
• Buchwald P., Bodor N. Octanol-water partition: searching for predictive models. Curr. Med. Chem. 1998; 5: 353
   PubMed Web of Science ®Google Scholar
• Bodor N., Huang M.-J. Computer-aided design of new drugs based on retrometabolic concepts. Computer-Aided Molecular Design: Applications in Agrochemicals, Materials, and Pharmaceuticals, C. H. Reynolds, M. K. Holloway, H. K. Cox. American Chemical Society, Washington, DC 1994; 98
   Google Scholar
• Bodor N., Huang M.-J. Computational approaches to the design of safer drugs and their molecular properties. Computational Chemistry: Reviews of Current Trends, J. Leszczynski. World Scientific, Singapore 1996; 1: 219
   Google Scholar
• Bodor N. Design of biologically safer chemicals. Chemtech. 1995; 25(10)22
   Google Scholar
• Bodor N., Buchwald P., Huang M.-J. Computer assisted design of new drugs based on retrometabolic concepts. SAR QSAR Environ. Res. 1998; 8: 41
   PubMed Web of Science ®Google Scholar
• Bodor N., Buchwald P., Huang M.-J. The role of computational techniques in retrometabolic drug design strategies. Computational Molecular Biology, J. Leszczynski. Elsevier, Amsterdam 1999; 569
   Google Scholar
• Bodor N. Novel approaches for the design of membrane transport properties of drugs. Design of Biopharmaceutical Properties through Prodrugs and Analogs, E. B. Roche. Academy of Pharmaceutical Sciences, Washington, DC 1977; 98
   Google Scholar
• Bodor N. Soft drugs: strategies for design of safer drugs. Strategy in Drug Research. Proceedings of the 2nd IUPAC-JUPHAR Symposium on Research, Noordwijkerhout, The Netherlands, J. A.K. Buisman. Elsevier, Amsterdam 11982; 137
   Google Scholar
• Bodor N. Novel approaches to the design of safer drugs: soft drugs and site-specific chemical delivery systems. Adv. Drug Res. 1984; 13: 255
   Google Scholar
• Bodor N. The soft drug approach. Chemtech. 1984; 14: 28
   Google Scholar
• Bodor N. Soft drugs. Encyclopedia of Human Biology, R. Dulbecco. Academic Press, San Diego 1991; 7: 101
   Google Scholar
• Bodor N., Buchwald P. Drug targeting via retrometabolic approaches. Pharmacol. Ther. 1997; 76: 1
   PubMed Web of Science ®Google Scholar
• Bodor N., Kaminski J. J., Selk S. Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials. J. Med. Chem. 1980; 23: 469
   PubMed Web of Science ®Google Scholar
• Bodor N., Kaminski J. J. Soft drugs. 2. Soft alkylating compounds as potential antitumor agents. J. Med. Chem. 1980; 23: 566
   PubMed Web of Science ®Google Scholar
• Bodor N., Woods R., Raper C., Kearney P., Kaminski J. Soft drugs. 3. A new class of anticholinergic agents. J. Med. Chem. 1980; 23: 474
   PubMedGoogle Scholar
• Bodor N. Designing safer drugs based on the soft drug approach. Trends Pharmacol. Sci. 1982; 3: 53
   Web of Science ®Google Scholar
• Korolkovas A. Essentials of Medicinal Chemistry. 2nd Ed., Wiley & Sons, New York 1988
   Google Scholar
• Nogrady T. Medicinal Chemistry. A Biochemical Approach. 2nd Ed., Oxford University Press, New York 1988
   Google Scholar
• Gillette J. R. Effects of induction of cytochrome P-450 enzymes on the concentration of foreign compounds and their metabolites and on the toxicological effects of these compounds. Drug Metab. Rev. 1979; 10: 59
   PubMed Web of Science ®Google Scholar
• Mannering G. J. Hepatic cytochrome P-450-linked drug-metabolizing systems. Concepts in Drug Metabolism part B, B. Testa, P. Jenner. Marcel Dekker, Inc., New York 1981; 53
   Google Scholar
• Bodor N., Varga M. Effect of a novel soft steroid on the wound healing of rabbit cornea. Exp. Eye Res. 1990; 50: 183
   PubMed Web of Science ®Google Scholar
• Druzgala P., Hochhaus G., Bodor N. Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J. Steroid Biochem. 1991; 38: 149
   Google Scholar
• Druzgala P., Wu W.-M., Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr. Eye Res. 1991; 10: 933
   PubMed Web of Science ®Google Scholar
• Alberth M., Wu W.-M., Winwood D., Bodor N. Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory corticosteroid. J. Biopharm. Sci. 1991; 2: 115
   Google Scholar
• Bodor N. S., Kiss-Buris S. T., Buris L. Novel soft steroids: effects on cell growth in vitro and on wound healing in the mouse. Steroids 1991; 56: 434
   PubMedGoogle Scholar
• Bodor N., Bodor N., Wu W.-M. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Curr. Eye Res. 1992; 11: 525
   PubMed Web of Science ®Google Scholar
• Bodor N., Loftsson T., Wu W.-M. Metabolism, distribution, and transdermal permeability of a soft corticosteroid, loteprednol etabonate. Pharm. Res. 1992; 9: 1275
   PubMed Web of Science ®Google Scholar
• Hochhaus G., Chen L.-S., Ratka A., Druzgala P., Howes J., Bodor N., Derendorf H. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J. Pharm. Sci. 1992; 81: 1210
   PubMed Web of Science ®Google Scholar
• Loftsson T., Bodor N. The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids. Adv. Drug Del. Rev. 1994; 14: 293
   Google Scholar
• Bodor N., Murakami T., Wu W.-M. Soft drugs. 18, Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats-for safer treatment of gastrointestinal inflammation. Pharm. Rev. 1995; 12: 869
   Google Scholar
• Bodor N., Wu W.-M., Murakami T., Engel S. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharm. Res. 1995; 12: 875
   PubMed Web of Science ®Google Scholar
• Reddy I. K., Khan M. A., Wu W.-M., Bodor N. S. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. J. Ocul. Pharmacol. Ther. 1996; 12: 159
   PubMedGoogle Scholar
• Bartlett J. D., Howes J. F., Ghormley N. R., Amos J. F., Laibovitz R., Horwitz B. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr. Eye Res. 1993; 12: 313
   PubMed Web of Science ®Google Scholar
• Bartlett J. D., Horwitz B., Laibovitz R., Howes J. F. Intraocular pressure response to loteprednol etabonate in known steroid responders. J. Ocul. Pharmacol. 1993; 9: 157
   PubMedGoogle Scholar
• Howes J. F., Baru H., Vered M., Neumann R. Loteprednol etabonate: comparison with other steroids in two models of intraocular inflammation. J. Ocul. Pharmacol. 1994; 10: 289
   PubMedGoogle Scholar
• Asbell P., Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J. 1997; 23: 31
   PubMedGoogle Scholar
• Dell S. J., Shulman D. G., Lowry G. M., Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Am. J. Ophthalmol. 1997; 123: 791
   PubMed Web of Science ®Google Scholar
• Friedlaender M. H., Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Am. J. Ophthalmol. 1997; 123: 455
   PubMed Web of Science ®Google Scholar
• Dell S. J., Lowry G. M., Northcutt J. A., Howes J., Novack G. D., Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J. Allergy Clin. Immunol. 1998; 102: 251
   PubMed Web of Science ®Google Scholar
• Howes J., Novack G. D. Failure to detect systemic levels and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. J. Ocul. Pharmacol. Ther. 1998; 14: 153
   PubMed Web of Science ®Google Scholar
• Novack G. D., Howes J., Crockett R. S., Sherwood M. B. Change in intraocular pressure during long-term use of loteprednol etabonate. J. Glaucoma 1998; 7: 266
   PubMed Web of Science ®Google Scholar
• Bodor N. The application of soft drug approaches to the design of safer corticosteroids. Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs, E. Christophers, A. M. Kligman, E. Schöpf, R. B. Stoughton. Raven Press Ltd., New York 1988; 13
   Google Scholar
• Bodor N. Design of novel soft corticosteroids. Topical Glucocorticoids with Increased Benefit-Risk Ratio, H. Korting. Karger AG, Basel 1993; 21: 11
   Google Scholar
• Druzgala P., Bodor N. Regioselectivc O-alkylation of cortienic acid and synthesis of a new class of glucocorticoids containing a 17α-alkoxy, a 17α-(1′-alkoxy-ethyloxy), a 17α-alkoxymethyloxy, or a l7α-methylthiomethyloxy function. Steroids 1991; 56: 490
   PubMedGoogle Scholar
• Dickerson J. E., Jr., Dotzel E., Clark A. F. Steroid-induced cataract: new perspectives from in vitro and lens culture studies. Exp. Eye Res. 1997; 65: 507
   PubMed Web of Science ®Google Scholar
• Heyns K., Koch W. Uber die Bildung eines Aminozuckers aus d-Fruktose und Ammoniak. Z. Naturforsch. B 1952; 7B: 486
   Google Scholar
• Bucala R., Fishman J., Cerami A. Formation of covalent adducts between cortisol and 16α-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 1982; 79: 3320
   PubMed Web of Science ®Google Scholar
• Bucala R., Gallati M., Manabe S., Cotlier E., Cerami A. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp. Eye Res. 1985; 40: 853
   PubMed Web of Science ®Google Scholar
• Urban R. C., Jr., Cotlier E. Corticosteroid-induced cataracts. Surv. Ophthalmol. 1986; 31: 102
   PubMed Web of Science ®Google Scholar
• Bodor N. Soft drugs: principles and methods for the design of safe drugs. Med. Res. Rev. 1984; 3: 449
   Google Scholar
• Bodor N. Prodrugs versus soft drugs. Design of Prodrugs, H. Bundgaard. Elsevier, Amsterdam 1985; 333
   Google Scholar
• Bodor N. Designing safer ophthalmic drugs. Trends in Medicinal Chemistry ‘88 Proceeding of the Xth International Symposium on Medicinal Chemistry, H. van der Goot, G. Domany, L. Pallos, H. Timmerman. Elsevier, Amsterdam 1989; 145
   Google Scholar
• The Loteprednol Etabonate Postoperative Inflammation Study Group 2, A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmology 1998; 105: 1780
   PubMed Web of Science ®Google Scholar
• Ophthalmology Times. Advanstar Communications Inc. September (1998)
   Google Scholar
• Bodor N., Brewster M. E. Problems of delivery of drugs to the brain. Pharmacol. Ther. 1983; 19: 337
   Web of Science ®Google Scholar
• Bodor N. Redox drug delivery systems for targeting drugs to the brain. Ann. NY Acad. Sci. 1987; 507: 289
   PubMed Web of Science ®Google Scholar
• Bodor N., Brewster M. E. Chemical delivery systems. Targeted Drug Delivery, R. L. Juliano. Springer-Verlag, Berlin 1991; 100: 231
   Google Scholar
• Bodor N., Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Delivery Rev. 1999; 36: 229
   PubMed Web of Science ®Google Scholar
• Design of Prodrugs, H. Bundgaard. Elsevier Science, Amsterdam 1985
   Google Scholar
• Bodor N., Kaminski J. J. Prodrugs and site-specific chemical delivery systems. Annu. Rep. Med. Chem. 1987; 22: 303
   Web of Science ®Google Scholar
• Stella V. J. Ed. Themed issue. Low molecular weight prodrugs. Adv. Drug Deliv. Rev. 1996; 19: 111
   Google Scholar
• Bodor N. New methods of drug targeting. Trends in Medicinal Chemistry ‘90, S. Sarel, R. Mechoulam, I. Agranat. Blackwell Scientific Publications, Oxford 1992; 35
   Google Scholar
• Bodor N. Drug targeting and retrometabolic drug design approaches. Adv. Drug Delivery Rev. 1994; 14: 157
   Web of Science ®Google Scholar
• Bodor N. Retrometabolic drug design concepts in ophthalmic target-specific drug delivery. Adv. Drug Delivery Rev. 1995; 16: 21
   Web of Science ®Google Scholar
• Bodor N. Targeting drugs to the brain by sequential metabolism. Discovery of Novel Opioid Medications, R. Rapaka, H. Sorer. NIDA, Rockville 1995; 147: 1
   Google Scholar
• Bodor N., Prokai L., Wu W.-M., Farag H. H., Jonnalagadda S., Kawamura M., Simpkins J. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 1992; 257: 1698
   PubMed Web of Science ®Google Scholar
• Bodor N., Farag H. H., Somogyi G., Wu W.-M., Barros M. D.C., Prokai L. Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs. J. Ocul. Pharmacol. 1997; 13: 389
   Google Scholar
• Bodor N., Prokai L. Molecular packaging: peptide delivery to the central nervous system by sequential metabolism. Peptide-Based Drug Design: Controlling Transport and Metabolism, M. Taylor, G. Amidon. American Chemical Society, Washington, DC 1995; 317
   Google Scholar
• Prokai-Tatrai K., Prokai L., Bodor N. Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J. Med. Chem. 1996; 39: 4775
   PubMed Web of Science ®Google Scholar
• Saah M., Wu W.-M., Eberst K., Marvanyos E., Bodor N. Design, synthesis, and pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue. J. Pharm. Sci. 1996; 85: 496
   PubMedGoogle Scholar
• Ishikura T., Senou T., Ishihara H., Kato T., Ito T. Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds. Int. J. Pharm. 1995; 116: 51
   Web of Science ®Google Scholar
• Pop E. Optimization of the properties of brain specific chemical delivery systems by structural modifications. Curr. Med. Chem. 1997; 4: 279
   Google Scholar
• Somogyi G., Nishitani S., Nomi D., Buchwald P., Prokai L., Bodor N. Targeted drug delivery to the brain via phosphonate derivatives. I. Design, synthesis, and evaluation of an anionic chemical delivery system for testosterone. Int. J. Pharm. 1998; 166: 15
   Google Scholar
• Somogyi G., Buchwald P., Nomi D., Prokai L., Bodor N. Targeted drug delivery to the brain via phosphonate derivatives. II. Anionic chemical delivery system for zidovudine (AZT). Int. J. Pharm. 1998; 166: 27
   Google Scholar
• Rydström J., Hoek J. B., Ernster L. The nicotinamide nucleotide transhydrogenases. The Enzymes, P. D. Boyer. Academic Press, New York 1976; 13
   Google Scholar
• Hoek J. B., Rydström J. Physiological roles of nicotinamide nucleotide transhydrogenase. Biochem. J. 1988; 254: 1
   PubMed Web of Science ®Google Scholar
• Bodor N., Brewster M. E., Kaminski J. J. Reactivity of biologically important reduced pyridines. Part III. Energetics and mechanism of hydride transfer between 1-methyl-1,4-dihydronicotinamide and the 1-methylnicotinamide cation, a theoretical study. J. Mol. Struct. (Theochem.) 1990; 206: 315
   Google Scholar
• Brewster M. E., Estes K. S., Perchalski R., Bodor N. A dihydropyridine conjugate which generates high and sustained levels of the corresponding pyridinium salt in the brain does not exhibit neurotoxicity in cynomolgus monkeys. Neurosci. Lett. 1988; 87: 277
   PubMedGoogle Scholar
• Bodor N., Roller R. G., Selk S. J. Elimination of a quaternary pyridinium salt delivered as its dihydropyridine derivative from brain of mice. J. Pharm. Sci. 1978; 67: 685
   PubMedGoogle Scholar
• Palomino E., Kessel D., Horwitz J. P. A dihydropyridine carrier system for sustained delivery of 1′, 3′-dideoxynucleosides to the brain. J. Med. Chem. 1989; 32: 622
   PubMed Web of Science ®Google Scholar
• Prokai L., Ouyang X.-D., Wu W.-M., Bodor N. Chemical delivery system to transport a pyroglutamyl peptide to the central nervous system. J. Am. Chem. Soc. 1994; 116: 2643
   Google Scholar
• Bodor N., Buchwald P. All in the mind. Chem. Br. 1998; 34(1)36
   Google Scholar
• Chen P., Bodor N., Wu W.-M., Prokai L. Strategies to target kyotorphin analogues to the brain. J. Med. Chem. 1998; 41: 3773
   PubMedGoogle Scholar
• Szejtli J. Medicinal applications of cyclodextrins. Med. Res. Rev. 1994; 14: 353
   PubMed Web of Science ®Google Scholar
• Brewster M. E., Estes K. E., Loftsson T., Perchalski R., Derendorf H., Mullersman G., Bodor N. Improved delivery through biological membranes. XXXI. Solubilization and stabilization of an estradiol chemical delivery system by modified β-cyclodextrins. J. Pharm. Sci. 1988; 77: 981
   PubMed Web of Science ®Google Scholar
• Anderson W. R., Simpkins J. W., Brewster M. E., Bodor N. Brain-enhanced delivery of testosterone using a chemical delivery system complexed with 2-hydroxy-propyl-β-cyclodextrin. Drug Des. Del. 1988; 2: 287
   PubMedGoogle Scholar
• Raghavan K., Loftsson T., Brewster M. E., Bodor N. Improved delivery through biological membranes. XLV. Synthesis, physical-chemical evaluation, and brain uptake studies of 2-chloroethyl nitrosourea delivery system. Pharm. Res. 1992; 9: 743
   PubMedGoogle Scholar
• Pop E., Loftsson T., Bodor N. Solubilization and stabilization of a benzylpenicillin chemical delivery system by 2-hydroxypropyl-β-cyclodextrin. Pharm. Res. 1991; 8: 1044
   PubMed Web of Science ®Google Scholar
• Kaplan N. M. Cardiovascular complications of oral contraceptives. Annu. Rev. Med. 1978; 29: 31
   PubMedGoogle Scholar
• Fotherby K. Oral contraceptives, lipids and cardiovascular disease. Contraception 1985; 31: 367
   PubMed Web of Science ®Google Scholar
• Lobo R. A. Benefits and risks of estrogen replacement therapy. Am. J. Obstet. Gynecol. 1995; 173: 982
   PubMed Web of Science ®Google Scholar
• Yager J. D., Liehr J. G. Molecular mechanism of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 1996; 36: 203
   PubMed Web of Science ®Google Scholar
• Upton G. V. Therapeutic considerations in the management of the climacteric. J. Reprod. Med. 1984; 29: 71
   PubMedGoogle Scholar
• Maggi A., Perez J. Role of female gonadal hormones in the CNS: clinical and experimental aspects. Life Sci. 1985; 37: 893
   PubMed Web of Science ®Google Scholar
• Yaffe K., Sawaya G., Lieberburg I., Grady D. Estrogen therapy in postmenopausal women—effects on cognitive function and dementia. JAMA—J. Am. Med. Assoc. 1998; 279: 688
   PubMed Web of Science ®Google Scholar
• Gopinath L. Outsmarting Alzheimer's disease. Chem. Br. 1998; 34(5)38
   Google Scholar
• Janocko L., Lamer J. M., Hochberg R. B. The interaction of C-17 esters of estradiol with the estrogen receptor. Endocrinology 1984; 114: 1180
   PubMed Web of Science ®Google Scholar
• Bodor N., McCornack J., Brewster M. E. Improved delivery through biological membranes. XXII. Synthesis and distribution of brain-selective estrogen delivery systems. Int. J. Pharm. 1987; 35: 47
   Google Scholar
• Simpkins J. W., McCornack J., Estes K. S., Brewster M. E., Shek E., Bodor N. Sustained brain-specific delivery of estradiol causes long-term suppression of luteinizing hormone secretion. J. Med. Chem. 1986; 29: 1809
   PubMedGoogle Scholar
• Anderson W. R., Simpkins J. W., Brewster M. E., Bodor N. Evidence for the reestablishment of copulatory behavior in castrated male rats with a brain- enhanced estradiol-chemical delivery system. Pharmacol. Biochem. Behav. 1987; 27: 265
   PubMedGoogle Scholar
• Estes K. S., Brewster M. E., Simpkins J. W., Bodor N. A novel redox system for CNS-directed delivery of estradiol causes sustained LH suppression in castrate rats. Life Sci. 1987; 40: 1327
   PubMed Web of Science ®Google Scholar
• Estes K. S., Brewster M. E., Bodor N. S. A redox system for brain targeted estrogen delivery causes chronic body weight decrease in rats. Life Sci. 1988; 42: 1077
   PubMedGoogle Scholar
• Anderson W. R., Simpkins J. W., Brewster M. E., Bodor N. Effects of a brain enhanced chemical delivery system for estradiol on body weight and serum hormones in middle-aged male rats. Endocr. Res. 1988; 14: 131
   PubMed Web of Science ®Google Scholar
• Brewster M. E., Estes K. S., Bodor N. Improved delivery through biological membranes. XXXII. Synthesis and biological activity of brain-targeted delivery systems for various estradiol derivatives. J. Med. Chem. 1988; 31: 244
   PubMedGoogle Scholar
• Mullersman G., Derendorf H., Brewster M. E., Estes K. S., Bodor N. High performance liquid chromatographic assay of a central nervous system (CNS)-directed estradiol chemical delivery system and its application after intravenous administration in rats. Pharm. Res. 1988; 5: 172
   PubMedGoogle Scholar
• Simpkins J. W., Anderson W. R., Dawson R., Jr., Seth E., Brewster M., Estes K. S., Bodor N. Chronic weight loss in lean and obese rats with a brain-enhanced chemical delivery system for estradiol. Physiol. Behav. 1988; 44: 573
   PubMedGoogle Scholar
• Simpkins J. W., Anderson W. R., Dawson R., Jr., Bodor N. Effects of a brain-enhanced chemical delivery system for estradiol on body weight and food intake in intact and ovariectomized rats. Pharm. Res. 1989; 6: 592
   PubMedGoogle Scholar
• Sarkar D. K., Friedman S. J., Yen S. C.S., Frautschy S. A. Chronic inhibition of hypothalamic-pituitary-ovarian axis and body weight gain by brain-directed delivery of estradiol-17β in female rats. Neuroendocr. 1989; 50: 204
   PubMedGoogle Scholar
• Brewster M. E., Simpkins J. W., Bodor N. Brain-targeted delivery of estrogens. Rev. Neurosci. 1990; 2: 241
   PubMedGoogle Scholar
• Brewster M. E., Bartruff M. S.M., Anderson W. R., Druzgala P. J., Bodor N., Pop E. Effect of molecular manipulation on the estrogenic activity of a brain-targeting estradiol chemical delivery system. J. Med. Chem. 1994; 37: 4237
   PubMedGoogle Scholar
• Estes K. S., Brewster M. E., Bodor N. Evaluation of an estradiol chemical delivery system (CDS) designed to provide enhanced and sustained hormone levels in the brain. Adv. Drug Del. Rev. 1994; 14: 167
   Google Scholar
• Simpkins J. W., Rajakumar G., Zhang Y.-Q., Simpkins C. E., Greenwald D., Yu C. J., Bodor N., Day A. L. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J. Neurosurg. 1997; 87: 724
   PubMed Web of Science ®Google Scholar
• Rabbani O., Panickar K. S., Rajakumar G., King M. A., Bodor N., Meyer E. M., Simpkins J. W. 17β-estradiol attenuates fimbrial lesion-induced decline of ChAT-immunoreactive neurons in the rat medial septum. Exp. Neurol. 1997; 146: 179
   PubMed Web of Science ®Google Scholar